Spontaneous Uterine Perforation of Choriocarcinoma with Negative Beta-Human Chorionic Gonadotropin after Chemotherapy

Chuan Xie   Lan Zheng   Zheng-Yu Li   Xia Zhao
Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, PR China

Key Words
Choriocarcinoma · Uterine perforation · Human chorionic gonadotropin · Hysterectomy

Abstract
Objective: To report an extremely rare case of spontaneous uterine perforation of choriocarcinoma with negative beta-human chorionic gonadotropin (β-hCG) post-chemotherapy.

Clinical Presentation and Intervention: We present a 35-year-old choriocarcinoma patient whose serial serum β-hCG levels following a fifth course of chemotherapy had been within the normal range, but who developed spontaneous uterine perforation with intra-abdominal hemorrhage after eight courses of combined chemotherapy. The patient then underwent an emergency hysterectomy and survived. Conclusion: Patients with persistent focus of disease in the uterus might experience uterine perforation even after adequate chemotherapy, and therefore, the follow-up for patients after chemotherapy is very important.

Introduction
Choriocarcinoma is a type of trophoblastic tumor, associated with aggressive biological behavior including local invasion of the uterus and metastasis to distant sites such as the lung and brain. The disease can often be cured by cytotoxic chemotherapy. Choriocarcinoma affects 1:40,000 pregnancies and 1:40 hydatidiform moles. However, choriocarcinoma presenting as spontaneous uterine perforation with intra-abdominal hemorrhage is extremely rare [1].

In this report, we describe a woman with spontaneous uterine perforation secondary to choriocarcinoma 3 months after β-human chorionic gonadotropin (β-hCG) normalized, who survived following emergency laparotomy and hysterectomy.

Case Report
A 35-year-old woman, gravida II, para I, abortion I, was admitted to our hospital with suspected choriocarcinoma. She had previously presented to a local hospital complaining of intermittent lower abdominal pain and irregular vaginal bleeding and was diagnosed with a hydatidiform mole. Curettage of the uterine cavity was then performed without pathological examination and follow-up for β-hCG. Nine months later, the patient presented again to hospital with irregular vaginal bleeding. The patient was admitted for further management of persistent trophoblastic disease.

On admission, bimanual examination revealed an enlarged uterus of 8–10 weeks gestation. Her serum β-hCG level was 88,994.5 mIU/ml, and transvaginal ultrasound revealed a complex mass in the uterus measuring 10 × 7 × 11 cm. Chest radiography showed bilateral multiple pulmonary nodules confirmed by computed tomography without evidence of brain or liver metastases.
With the above findings, the patient was diagnosed with metastatic choriocarcinoma stage III FIGO in the WHO scoring system, at high-risk category. Combined chemotherapy was initiated as follows: 5-fluorouracil (5-FU) 24 mg/kg·day and kengsengmycin (KSM) 6 μg/kg·day intravenously from day 1 to day 8. The above regimen was repeated at a 3-week interval. Serum β-hCG levels decreased in a time-dependent manner and normalized after five courses of chemotherapy (fig. 1). Serial chest X-ray also showed the gradually diminishing pulmonary infiltrates, which completely resolved after the fourth chemotherapy. Transvaginal ultrasound revealed that the intrauterine mass was 2.6 cm in diameter after the fifth chemotherapy. Because of refusal of surgical treatment by the patient, three additional courses of chemotherapy were performed as consolidation therapy. Serum β-hCG levels during the three additional courses remained normal, and ultrasound revealed no pronounced change in the size of carcinoma foci.

One month after the end of chemotherapy, the patient was admitted to the emergency room for acute lower abdominal pain and sudden vaginal bleeding. Abdominal ultrasound findings showed an enlarged uterus and blood clots in the pelvic cavity, and temporarily β-hCG was not obtained. On suspicion of uterine perforation secondary to choriocarcinoma (fig. 1). Serial chest X-ray also showed the gradually diminishing pulmonary infiltrates, which completely resolved after the fourth chemotherapy. Transvaginal ultrasound revealed that the intrauterine mass was 2.6 cm in diameter after the fifth chemotherapy. Because of refusal of surgical treatment by the patient, three additional courses of chemotherapy were performed as consolidation therapy. Serum β-hCG levels during the three additional courses remained normal, and ultrasound revealed no pronounced change in the size of carcinoma foci.

Histopathologic examination revealed large amounts of degenerative trophoblast cells in the posterior uterine wall around which extensive hyaline change, focal calcification and foreign body giant cell reaction of smooth muscle were detected, which were in accordance with postchemotherapy changes of choriocarcinoma (fig. 2).

After 7 days’ hospitalization, the patient was discharged with a follow-up plan for serial β-hCG measurement. At present, 17 months after surgery, the patient is well with normal levels of β-hCG and without signs of recurrence.

**Discussion**

Gestational choriocarcinoma arising from placental trophoblastic tissue is a malignant germ cell tumor that can be associated with any type of gestational event, most often a complete hydatidiform mole [2]. Early metastasis to distant sites, especially to the lungs, liver, and brain, is quite common.

It is widely accepted that patients with choriocarcinoma are best managed by stratifying their treatment according to the recognized adverse prognostic features. According to the FIGO 2000 scoring system, most patients with a score of 6 or less should be classified as low-risk and treated with single-agent chemotherapy, while those with a score of 7 or more should be categorized as high-risk and combined chemotherapy initiated, such as 5-FU + KSM and EMA-CO regimes [3]. The patient in this report began with the 5-FU + KSM chemotherapy regime. Her serum β-hCG decreased from 88,994.5 to 100,000, 10,000, 1,000, 100, 10, 1.0, 0.1 mIU/ml following the fifth course of chemotherapy.
10,351.8 after the first course of chemotherapy and became negative after five courses (fig. 1). The falling of serum β-hCG level demonstrated the effectiveness of the multichemotherapy regime for this patient.

hCG secreted by cytotrophoblastic cells is composed of two polypeptide subunits: α and β, and the β chain is unique to hCG [4]. Serum β-hCG is generally intact during the first trimester of healthy pregnancy. However, many other forms of β-hCG, including β-core, free-β-hCG, or nicked free-β, can exist in cancers like choriocarcinoma, which may be the reason why some commercial assays fail to detect some cancer-specific subtypes [5]. In our case, several different commercial assays were applied to eliminate a possible false-negative result.

During chemotherapy treatment, β-hCG is a useful tumor marker to monitor the patient’s response to treatment and assess the focus of disease in the uterus. In our case, the pulmonary lesions disappeared after four courses of chemotherapy and serial weekly β-hCG was negative following the fifth course (fig. 1). The size of disease foci localized in the patient’s posterior uterine wall diminished from 7 to 2.6 cm in diameter during the five courses of chemotherapy, but it persisted during the three additional courses of consolidation chemotherapy. Previous studies have postulated that when hCG titers become undetectable, chemotherapy can be discontinued after two to three additional courses [6, 7]. As the concentration of serum β-hCG reflects the amount of viable trophoblastic tissue, a negative β-hCG result may clinically reflect the absence of invasive cytotrophoblasts that could invade normal myometrium and cause uterine perforation. However, in our case, the patient developed spontaneous uterine perforation after 3 months with negative β-hCG. According to some studies, tumors like choriocarcinoma are hypervascular and can cause uterine perforation due to myometrial invasion [8, 9]. Trophoblastic cells can invade blood vessels in the uterus. The damaged blood vessels may thrombose and result in single or multiple infarctions. Blood vessels may also develop tumorous aneurysms and bleed into the tissues surrounding the tumor or tumor tissue [1, 10]. For this case, the exact cause of spontaneous uterine perforation of choriocarcinoma remains unclear. A possible explanation is that the effective treatment, which killed off the trophoblastic tissue, resulted in an area of necrosis large enough to cause a spontaneous perforation to develop in the uterus. It is difficult to determine whether choriocarcinoma cells could be eradicated completely when a negative β-hCG
Uterine perforation of choriocarcinoma is rare, and it is even rarer when hCG becomes negative for 3 months after chemotherapy. To the best of our knowledge, no similar cases have been reported previously.

Conclusion

A negative hCG titer does not always indicate the disappearance of viable choriocarcinoma cells and the complete cure of choriocarcinoma, and may instead relate to the sensitivity of the assay. It is suggested that patients with persistent focus of disease in the uterus may experience uterine perforation even after adequate chemotherapy, and the follow-up for patients after chemotherapy is very important. When patients develop such emergencies as acute intraperitoneal bleeding, abdominal pain or shock, indicating the possibility of uterine perforation, surgical treatment might be necessary and optimal, and hysterectomy is generally recommended for most cases.

References